Skip to main content

Table 1 Demography and severity of illness data

From: The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study

 

Controls

ECMO

No RRT

RRT

No RRT

RRT

(n = 5)

(n = 5)

(n = 6)

(n = 5)

Male/Female

3/2

3/2

1/5

3/2

Age (years)

55.0 (48–61)

56 (46–66)

29 (16–46)

38 (23–56)

Total body weight (kg)

80 (75–85)

70 (60–100)

69 (60–80)

70 (70–76)

Mechanical ventilation

5/5

5/5

5/5

5/5

Type of ECMO (VA/VV)

0/0

0/0

3/3

2/3

Day 1 SOFA score

3 (3–4)

15 (14–16)

9 (7–14)

16 (13–17)

Plasma creatinine concentration (μmol/L)

73 (55–101)

na*

75 (44–82)

na*

Creatinine clearance (mL/min)

106 (98–127)

na*

108 (65–183)

na*

RRT mode

-

CVVH

-

EDD-f

Serum bilirubin (μmol/L)

9 (5–23)

93 (36–115)

23 (9–73)

58 (34–134)

Serum albumin (g/L)

22 (18–36)

26 (23–36)

31 (27–35)

24 (22–32)

Serum proteins (g/L)

56 (55–70)

62 (60–65)

49 (46–54)

44 (34–56)

Meropenem daily dose (g)

1 q 8 h

1 q 8 h

1 q 8 h

1q 8 h

Plasma C max (mg/L)

93 (74–119)

58 (52–68)

42 (27–56)

59 (50–86)

Plasma C min (mg/L)

0 (0–2)

7.5 (5–18)

4.9 (2–10)

18 (7–43)

  1. *Patients RRT dependent. The biochemical indices were measured on day of pharmacokinetic sampling. Data are presented as median (IQR). ECMO, extracorporeal membrane oxygenation; RRT, renal replacement therapy; VA, venoarterial; VV, venovenous; SOFA, sequential organ failure assessment; CVVH, continuous venovenous haemofiltration; EDD-f, extended daily diafiltration.